This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AEZS-130 (Therapeutic)

AEterna Zentaris, Inc.

Drug Names(s): EP-1572, ARD-07, Growth Hormone Secretagogue (GHS), macimorelin

Description: BioMedTracker has two separate profiles for the therapeutic and diagnostic development of AEZS-130. Please also see AEZS-130 (Diagnostic).

AEZS-130 is an orally administered non-peptidyl growth hormone secretagogue, which stimulates the release of growth hormone. It is thought to work without the involvement of Growth Hormone Releasing Hormone (GH-RH) or somatostatin. Its target is the ghrelin receptor, formally known as the growth hormone secretagogue receptor.

Deal Structure: AEterna Zentaris and Ardana
In 2002, AEterna Zentaris granted Ardana an exclusive worldwide license to develop and market the growth hormone secretagogue EP-1572. Ardana is funding the activities necessary to obtain regulatory and marketing approvals. Furthermore, the agreement provides milestone payments, as well as royalties on future worldwide net sales of EP-1572 among other elements to AEterna Zentaris.

In November 2008, AEterna announced that it has recovered worldwide rights from Ardana plc for AEZS-130.


AEZS-130 (Therapeutic) News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug